RNA therapeutics
A practical roadmap for managing elevated Lp(a) today, from apheresis's 60-75% cut to RNA agents' 80-95%, while outcomes trials are pending (Semin Thromb Hemost 2025)
Original title: Clinical Response to Elevated Lipoprotein(a): Practical Approach for Risk Management in the Absence of Targeted Therapies
This practical review by Sanchis-Gomar and Lippi surveys current options for managing elevated lipoprotein(a) in the absence of an outcome-proven Lp(a)-specific therapy. Statins, ezetimibe, bempedoic acid and lifestyle measures have little or no effect on Lp(a), and niacin is now contraindicated after failing to show a mortality benefit; PCSK9 inhibitors and inclisiran lower Lp(a) by roughly 20 to 30%, secondary to their LDL-C effect. Lipoprotein apheresis, the only FDA-approved Lp(a)-specific therapy, cuts levels by 60 to 75% but is invasive, costly and restricted to select patients. RNA-based agents in trials, the antisense oligonucleotide pelacarsen and the siRNAs olpasiran, lepodisiran and SLN360, achieve sustained reductions of 80 to 95%, with outcomes trials still needed to confirm clinical benefit. The authors recommend one-time lifetime Lp(a) measurement, treating 125 nmol/L (50 mg/dL) or above as risk-enhancing, and aggressive risk-factor management, cascade screening, and apheresis or trial referral for extreme elevations.
Original abstract
Lipoprotein(a) (Lp(a)) is a genetically determined, lifelong cardiovascular risk factor strongly associated with atherosclerotic cardiovascular disease (ASCVD) despite optimal low-density lipoprotein cholesterol (LDL-C) lowering. The current management is challenged by the absence of outcome-proven Lp(a)-specific therapies. Statins, ezetimibe, bempedoic acid, and lifestyle interventions have little or no effect on Lp(a). Statins may modestly raise levels; niacin is now contraindicated as it has not been shown to reduce cardiovascular or all-cause mortality, while PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) inhibitors and inclisiran reduce Lp(a) concentrations by approximately 20 to 30%, though this effect remains secondary to their LDL-C-lowering effect. The only U.S. Food and Drug Administration (FDA)-approved therapy specifically addressing Lp(a) is lipoprotein apheresis, which reduces Lp(a) levels by 60 to 75%, but is restricted to specific patient populations due to invasiveness, high cost, and limited availability. Future promise lies in RNA-based therapies, including antisense oligonucleotides (pelacarsen) and small-interfering RNAs (olpasiran, lepodisiran, SLN360), which achieve 80 to 95% sustained Lp(a) reductions. Large outcome trials will determine whether this biochemical efficacy translates into tangible clinical benefits. Current guidelines now recommend one-time lifetime Lp(a) measurement, treating ≥125 nmol/L (≥50 mg/dL) as a risk-enhancing factor. High or extreme elevations, especially with ASCVD, mandate aggressive LDL-C lowering, optimization of modifiable risk factors, family cascade screening, and apheresis or referral to RNA-therapy trials in select cases. Thus, while therapeutic options remain limited, systematic measurement and risk stratification are ethically justified to prepare for the imminent arrival of Lp(a)-targeted therapies.
apheresisguidelinesRNA therapeuticstherapy
Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.